Evogene (NASDAQ:EVGN) announced a fundamental strategic refocusing alongside its fourth-quarter and full-year 2025 financial results, moving to concentrate its resources on its proprietary ChemPass AI™ tech-engine.
Stratasys (NASDAQ:SSYS) shares fell more than 6% in pre-market trading, Thursday after the company provided a 2026 financial outlook that suggests continued headwinds for the additive manufacturing sector, despite a fourth-quarter earnings performance that beat expectations.
Ciena (NYSE:CIEN) delivered a strong start to its fiscal 2026, reporting first-quarter results that comfortably cleared Wall Street’s bar on both the top and bottom lines.
The Buckle (NYSE:BKE) saw a sharp acceleration in sales growth during February, outperforming the low-single-digit gains seen at the close of its previous fiscal year.
BJ’s Wholesale Club Holdings (NYSE:BJ) posted a 10.9% increase in membership fee income and robust digital growth in its fiscal fourth quarter, signaling resilient consumer demand for the warehouse club model despite a cooling inflationary environment.
The Kroger Company (NYSE:KR) reported full-year 2025 sales of $147.6 billion and issued a 2026 guidance that signals steady growth, even as the retailer navigates the tail end of a major strategic shift in its automated fulfillment network.
Liquidia (NASDAQ:LQDA) reported a surge in fourth-quarter revenue and achieved a critical milestone of quarterly profitability, fueled by the rapid market adoption of YUTREPIA following its June 2025 launch.
Teads Holding (NASDAQ:TEAD) reported a 46% increase in full-year revenue for 2025, a performance primarily driven by the transformative acquisition and integration of legacy Teads.
Ituran Location and Control (NASDAQ:ITRN) reported record-breaking financial results for the full year 2025, characterized by strong subscriber growth and peak levels of revenue and profitability.
Shattuck Labs (NASDAQ:STTK) reported a narrowed net loss for fiscal year 2025, driven by a strategic reduction in research and development expenses and a disciplined focus on its lead clinical programs.
HUTCHMED (NASDAQ:HCM) reported a net income of $456.9 million for the full year 2025, a nearly 12-fold increase from the prior year, primarily driven by a one-time divestment gain and the continued global expansion of its oncology portfolio.
Palladyne AI (NASDAQ:PDYN) reported a significant year-over-year revenue increase for the fourth quarter of 2025, marking the beginning of a major operational transition toward becoming a mid-tier defense prime contractor.
